Cala and Maclean Health Partner to Expand Veteran Access for the Cala kIQ Plus System for Hand Tremor in Essential Tremor and Parkinson’s Disease
PR Newswire
SAN MATEO, Calif., Nov. 11, 2026
Maclean Health, a Service-Disabled Veteran-Owned Small Business, will be the exclusive VA distributor of the first and only wearable neurostimulation device with multiple waveform modes and adaptive calibration
SAN MATEO, Calif., Nov. 11, 2026 /PRNewswire/ — Cala®, the bioelectronic medicine leader, today announced availability of the Cala kIQ® Plus System, the latest advancement of its wearable neurostimulation device for action hand tremor in essential tremor (ET) and Parkinson’s disease (PD), for eligible veterans through its partnership with Maclean Health, a certified Service-Disabled Veteran-Owned Small Business (SDVOSB). The Cala kIQ Plus System, which features the most advanced TAPS® therapy, is available to VA medical centers nationwide on the Federal Supply Schedule (FSS).
Cleared by the FDA earlier this year, the Cala kIQ Plus is the first and only wearable for hand tremor to offer multiple stimulation waveform modes, which users can choose and change at any time along with adaptive calibration to personalize therapy.
ET affects an estimated 7 million Americans, and action hand tremor from Parkinson’s disease adds more to the population living with a condition that disrupts basic daily activities like eating, drinking, dressing, and self-care – often with downstream effects on mental health and social participation. Historically, treatment options have been limited to medications that are not tremor-specific and carry side effects or invasive interventions. Many patients discontinue medications due to lack of efficacy or intolerable side effects. Cala TAPS therapy fills that treatment gap with a clinically proven, effective non-invasive wearable with long term real-world evidence spanning over three years.
“On Veterans Day, we honor those who have served our country, and we are proud to partner with Maclean Health, a veteran-owned healthcare solutions distributor on the Federal Supply Schedule, to bring our most advanced Cala TAPS technology, the Cala kIQ Plus System, to veterans living with hand tremor,” said Cala CEO Deanna Harshbarger. “Cala TAPS therapy is a clinically validated and effective option for veterans, and this partnership will continue to expand access for VA providers to help veterans experiencing tremor.”
“Maclean Health is committed to delivering high quality, innovative healthcare products to the VA and the veterans it serves,” said Rear Admiral (ret.) Louis Tripoli, M.D., Chief Medical Officer of Maclean Health. “We know the options for patients with hand tremor are limited, have poor side effects or are invasive. The Cala kIQ Plus is a valuable noninvasive option to provide for those we serve.”
The Cala kIQ Plus device is available through the VA Health System at no cost to eligible beneficiaries, with a prescription from a VA healthcare provider. Maclean Health exclusively distributes Cala products to VA medical centers across the United States and has added them to its contracts on the Federal Supply Schedule (FSS 65 II A). Inquiries related to FSS purchasing and order processing should be directed to Maclean Health at cala_orders@macleanhealth.com or (800) 683-4923. Cala will continue to support VA healthcare providers and veterans; contact Cala at customercare@calahealth.com or (888) 699-1009.
About Cala®
Cala Health® is a bioelectronic medicine company transforming the standard of care for chronic disease. The company’s wearable neuromodulation therapies merge innovations in neuroscience and technology to deliver individualized peripheral nerve stimulation, and its direct-to-home digital durable medical equipment (DME) platform is reshaping the delivery of prescription therapies.
The Cala kIQ® Plus System is the only FDA-cleared wearable device that delivers effective therapy for action hand tremor in people with essential tremor and Parkinson’s disease. The Cala kIQ Plus device is indicated to aid in the temporary relief of hand tremors in the treated hand following stimulation in adults with essential tremor. The Cala kIQ Plus device is indicated to aid in the temporary relief of postural and kinetic hand tremor symptoms that impact some activities of daily living in the treated hand following stimulation in adults with Parkinson’s disease. The Cala kIQ Plus device delivers TAPS™ therapy, which provides transcutaneous afferent patterned stimulation. Caution: Federal law restricts this device to sale by or on the order of a physician. Prior to use, refer to the product labeling for complete product instructions for use, contraindications, warnings, and precautions at CalaHealth.com/Safety.
View original content:SOURCE Cala Health
